CMAHP

Across TCGA pan-cancer cohorts, CMAHP Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CMAHP data layer compared with 27 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher CMAHP Mutation is associated with better overall survival. In most high-consensus cancer types, elevated CMAHP expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

ESCA, UCEC, and COAD are the cancer types where CMAHP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.506	0.473	<.001	7	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	DFS	Median	III,IV	0.263	0.652	.018	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CMAHP–ESCA (OS)

Open the ESCA breakdown →